EARLY ADMINISTRATION OF LETERMOVIR PROPHYLAXIS POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IS ASSOCIATED WITH DELAYED ENGRAFTMENT (EBMT 2026) - Mar 14, 2026 - Abstract #B099; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Patient characteristics were similar between the 2 periods except for higher rates in the post-letermovir period of peripheral blood versus bone marrow stem cells for HCT sources, and of cyclophosphamide-based regimens for GvHD prophylaxis. In our cohort, engraftment is slightly but significantly delayed in allo-HCTR+ receiving letermovir compared to the pre-letermovir period, despite the reduction in post-HCT CMV reactivation incidence and improved survival. In the literature, few studies report on engraftment but 5/9 studies also find delayed engraftment in letermovir-receiving patients. This effect is independent of other tested covariables and could be due to the drug itself or virus-mediated."
Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation
|
|
Léna Royston1; Catia Vieira Gomes1; Ming Zou2; Yves Chalandon1; Stavroula Masouridi-Levrat1; Laurent Kaiser1; Christian Van Delden1; Dionysios Neofytos1
|